1. Home
  2. OGEN vs CNSP Comparison

OGEN vs CNSP Comparison

Compare OGEN & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.97

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

N/A

Current Price

$3.12

Market Cap

1.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OGEN
CNSP
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
1.8M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
OGEN
CNSP
Price
$0.97
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
432.2K
17.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
82.57
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.73
52 Week High
$9.16
$10.59

Technical Indicators

Market Signals
Indicator
OGEN
CNSP
Relative Strength Index (RSI) 68.54 37.52
Support Level $0.78 $0.77
Resistance Level $1.02 $8.89
Average True Range (ATR) 0.09 0.23
MACD 0.03 0.11
Stochastic Oscillator 94.43 92.73

Price Performance

Historical Comparison
OGEN
CNSP

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Share on Social Networks: